3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
311
Neoplasm Metastasis
38
Neoplasms
22
Advanced Breast Cancer
19
Ovarian Neoplasms
18
Carcinoma, Non-Small-Cell Lung
14
Endometrial Neoplasms
11
Prostatic Neoplasms
10
Hereditary Sensory and Autonomic Neuropathies
10
Triple Negative Breast Neoplasms
8
Colorectal Neoplasms
6
Breast Cancer Metastatic
6
Uterine Cervical Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
5
Recurrence
5
Carcinoma, Ovarian Epithelial
5
Neoplasms by Site
4
Multiple Endocrine Neoplasia Type 1
4
Breast Diseases
4
Stomach Neoplasms
3
Small Cell Lung Carcinoma
3
Lung Neoplasms
3
Head and Neck Neoplasms
3
Fallopian Tube Neoplasms
3
Carcinoma, Lobular
3
Uterine Neoplasms
2
Pancreatic Neoplasms
2
Melanoma
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Interventions
abemaciclib
1
Trastuzumab
1
Fulvestrant
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Hormone Receptor Positive Breast Cancer
×
Fulvestrant
×
Clear all
NCT02675231
2024-11-26
monarcHER
Eli Lilly and Company
Phase 2
Completed
237 enrolled
25 charts